The race to build a better Duchenne therapy

Overview

Boys born with Duchenne muscular dystrophy typically lose the ability to walk before their teens and rarely live past 30. The first drugs designed to slow that decline reached the market in 2016, but they restore less than 1% of normal dystrophin, the muscle protein patients are missing. A decade later, a new wave of biotech companies is trying to deliver far more of that protein into muscle cells using engineered molecular shuttles.

Why it matters

Better delivery technology could turn Duchenne from a fatal childhood disease into a manageable one for thousands of boys worldwide.

Key Indicators

<1%

Dystrophin from approved drugs

First-generation exon-skipping therapies restore less than one percent of normal dystrophin protein.

~6-10%

Patients eligible for exon-44 skipping

Roughly 900 boys in the United States carry mutations that exon-44 skipping could treat.

25%

Dystrophin from Avidity rival drug

Avidity's del-zota produced about 25% of normal dystrophin in early 2025 trial data.

6 mg/kg

Entrada Cohort 1 dose

First patient cohort received this dose in the ELEVATE-44-201 study.

26 months

Duration of FDA clinical hold

Entrada's program was paused in the United States from December 2022 to February 2025.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Dipal Doshi

Leading first efficacy readout for the EEV platform

Sarah Boyce

Preparing accelerated-approval filing for competing exon-44 drug

Organizations Involved

Entrada Therapeutics

Biotechnology Company

Reporting first human efficacy data for EEV platform

Boston biotech developing cyclic cell-penetrating peptides that ferry oligonucleotide drugs into the inside of muscle cells.

Avidity Biosciences

Biotechnology Company

Leading exon-44 race with 25% dystrophin data

San Diego biotech that conjugates oligonucleotide drugs to antibodies targeting muscle-cell receptors.

Sarepta Therapeutics

Biotechnology Company

Incumbent leader facing safety setbacks

Owns three of the four approved exon-skipping drugs and the only approved Duchenne gene therapy, Elevidys.

U.S. Food and Drug Administration

Federal Regulatory Agency

Reviewing safety and efficacy of next-generation candidates

United States regulator that approves new drugs and oversees clinical trials.

Timeline

Entrada releases first human efficacy data
Clinical

Entrada announces topline Cohort 1 results from the Phase 1/2 ELEVATE-44-201 study, the first efficacy readout for the EEV platform in Duchenne patients.
Today
FDA adds black-box warning to Sarepta gene therapy
Regulatory

After three deaths from acute liver failure, FDA imposes a boxed warning on Elevidys and limits its use to ambulatory patients aged four and older.
November 17th, 2025
Avidity reports patient data and breakthrough designation
Clinical

Del-zota produces about 25% of normal dystrophin and near-normal creatine kinase in DMD patients. FDA grants Breakthrough Therapy designation, and Avidity plans an accelerated-approval filing.
March 3rd, 2025
FDA lifts hold on Entrada program
Regulatory

After 26 months, FDA authorizes Entrada to begin a Phase 1b multiple ascending dose trial of ENTR-601-44 in adult Duchenne patients in the United States.
February 24th, 2025
Avidity reports first proof-of-concept data
Clinical

Avidity Biosciences announces dystrophin restoration with del-zota in early trial data, validating its antibody-oligonucleotide conjugate platform.
July 8th, 2024
Sarepta wins approval for first Duchenne gene therapy
Regulatory

FDA grants accelerated approval to Elevidys, a one-time gene therapy that delivers a shortened dystrophin gene using a viral vector.
June 22nd, 2023
FDA pauses Entrada Duchenne program
Regulatory

FDA places a clinical hold on Entrada's investigational new drug application for ENTR-601-44, blocking US patient trials. Entrada moves early studies to the United Kingdom.
December 2nd, 2022
Entrada goes public
Corporate

Entrada Therapeutics completes its initial public offering on Nasdaq, raising capital to advance its Endosomal Escape Vehicle platform into human trials.
October 29th, 2021
First Duchenne exon-skipping drug approved
Regulatory

FDA grants accelerated approval to Sarepta's eteplirsen despite advisors voting against it, citing dystrophin restoration of less than 1% as a surrogate marker.
September 19th, 2016

Scenarios

Entrada matches Avidity, validating a two-horse race

Discussed by: Equity analysts at Guggenheim and Stifel covering rare-disease biotech

Cohort 1 produces double-digit dystrophin restoration, in the same range as Avidity's 25% benchmark. Entrada continues into higher-dose cohorts and positions for accelerated approval roughly 18 months behind Avidity. Both EEV and antibody-conjugate platforms become validated for broader exon-skipping franchises and other muscle diseases.

Disappointing data sends Entrada back to higher doses

Discussed by: Sell-side biotech analysts and Duchenne patient organizations

Cohort 1 produces only single-digit dystrophin at the 6 mg/kg dose, below internal projections. Entrada points to its 12 mg/kg and higher cohorts, due later in 2026, as the real test. The stock falls sharply but the program continues, with the higher-dose readouts becoming the make-or-break catalyst.

Safety signal halts the program

Discussed by: FDA reviewers and Duchenne patient advocacy groups

The trial reveals liver enzyme elevations or other adverse events that echo earlier concerns about cell-penetrating peptide chemistry. Given the Elevidys precedent, FDA pauses dosing or requires additional safety monitoring. The setback would not end the EEV platform but would add years to its timeline.

Breakthrough data resets the entire field

Discussed by: Duchenne researchers and biotech investors

Cohort 1 produces dystrophin restoration well above the Avidity benchmark, suggesting the EEV platform delivers more drug to muscle than antibody conjugates. The result would attract a large-pharma acquirer and shift competitive dynamics across the exon-44, exon-45, exon-51 and exon-53 programs Entrada also has in early development.

Historical Context

Eteplirsen accelerated approval (2016)

September 2016

What Happened

FDA approved Sarepta's eteplirsen for Duchenne despite an advisory committee voting 7-3 that the data did not show effectiveness. The approval was based on dystrophin restoration of less than 1% in 12 patients, with no functional benefit demonstrated. FDA reviewer Ellis Unger called the evidence inadequate; Commissioner Robert Califf overruled him.

Outcome

Short Term

Sarepta priced eteplirsen at roughly $300,000 per patient per year. Patient advocates celebrated, but mainstream physicians questioned whether the drug worked.

Long Term

The decision established dystrophin restoration as an acceptable surrogate marker for accelerated approval, paving the way for three more exon-skipping drugs and the entire next generation of EEV and antibody-conjugate programs.

Why It's Relevant Today

Today's regulatory pathway for ENTR-601-44 and del-zota exists because of the eteplirsen precedent. The low bar set in 2016 is exactly what new entrants are trying to dramatically clear with better delivery technology.

Spinraza approval transforms spinal muscular atrophy (2016)

December 2016

What Happened

FDA approved Biogen's Spinraza, an antisense oligonucleotide injected into the spinal canal, for spinal muscular atrophy. The drug increased survival motor neuron protein production and produced dramatic motor function improvements in infants who had previously faced near-certain death.

Outcome

Short Term

Spinraza became a multi-billion-dollar drug and made spinal muscular atrophy the textbook example of how oligonucleotide therapy can transform a fatal pediatric neuromuscular disease.

Long Term

The success encouraged investment across oligonucleotide platforms targeting Duchenne, myotonic dystrophy, and other rare neuromuscular conditions. It also raised expectations: investors and patients now ask why Duchenne drugs cannot match Spinraza's effect size.

Why It's Relevant Today

Spinraza shows what is possible when an oligonucleotide reaches its target tissue at sufficient concentration. The next-generation Duchenne race is essentially an attempt to replicate that delivery success in a much harder tissue: skeletal muscle.

Elevidys boxed warning (2025)

November 2025

What Happened

FDA imposed a black-box warning on Sarepta's Elevidys gene therapy after three patients died of acute liver failure following infusion. The agency narrowed the label to ambulatory patients aged four and older, removing the non-ambulatory indication granted just a year earlier. Sarepta cut roughly 500 jobs.

Outcome

Short Term

Elevidys revenue projections fell sharply. Sarepta's stock dropped, and patient families faced new uncertainty about the only approved gene therapy for the disease.

Long Term

The setback opens commercial space for exon-skipping competitors and increases pressure on FDA to scrutinize new Duchenne approvals. It also reminds the field that one-time gene therapies carry irreversible risks that repeated-dose oligonucleotides do not.

Why It's Relevant Today

The Elevidys warning shifted the competitive landscape that Entrada and Avidity now occupy. With gene therapy facing safety scrutiny, the next-generation oligonucleotide approach has both a bigger market opportunity and a more cautious regulator to navigate.